Intas

Intas operates through Intas Pharmaceuticals Limited (active). Its filings, financials, charges and directors are on the company page.

Last known valuation $866.44M (Apr 2012). 2 investors in total: 2 institutional.

Intas has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include ChrysCapital and Tata Capital Healthcare Fund.

All

Venture Fund

Investor	Description	Founded Year	Domain	Location
ChrysCapital	Investment firm focusing on private equity in sectors like financial services and healthcare.	1999	chryscapital.com
Tata Capital Healthcare Fund			tatacapitalhealthcarefund.com

Premium access

Investor details for Intas

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

• Complete investor list
• Round participation
• Investor portfolios
• Co-investor network

Access investors

Verified entity values are shown only after access is granted.

Intas Pharmaceuticals Limited is the primary company behind Intas. The board of Intas Pharmaceuticals Limited currently have 9 directors; the longest-serving is Hasmukh Chudgar, appointed in 1985. 19 earlier directors have ceased.

115 people are tracked at Intas (51 in leadership, 64 in team); the tracked headcount is 19,974.

95 more people are available in the full profile.

Figures of Intas Pharmaceuticals Limited, the primary company behind Intas, for FY 2026. Revenue was ₹15,434 Cr (+33% year on year). Net profit was ₹1,543 Cr (5% margin). EBITDA was ₹4,371 Cr (16% margin). Revenue has grown at a compounded annual rate of +12% over three years and +11% over five years.

• ₹15,434 CrRevenue · FY 2026 · +33% YoY
• ₹1,543 CrNet profit · 5% margin
• ₹4,371 CrEBITDA · 16% margin
• ₹115 CrPaid-up capital
• 19,974Employees (provident fund records)
• +12%Revenue CAGR, 3 years
• +11%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Intas Pharmaceuticals Limited are on its company page.

Intas has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bioxel Pharma and Udenyca.

6 dated milestones of Intas across 47 years, from founding to its latest funding, stage changes and deals.

1. 1977 Founded Intas is founded.
2. Jun 2005 Funding First funding round of $11.5M.
3. Mar 2009 Acquisition Acquires Bioxel Pharma.
4. Apr 2012 Milestone Reaches Soonicorn status.
5. Jun 2020 Funding Latest funding round, Private Equity Round, of $132.0M.
6. Dec 2024 Acquisition Acquires Udenyca.

The website of Intas (intaspharma.com) receives about 153.7K visits a month.

• Monthly visits
  153.7K

  ▼ 5.7% vs previous month

Websites whose visitors overlap most with Intas. Affinity shows how closely the audiences match.

Website	Domain	Audience affinity	Monthly visits	Global rank	Profile
ijpsonline.com	ijpsonline.com	100%		#907,151	–
MedicinesComplete	medicinescomplete.com	100%		#70,803	View details
Pharmabiz	pharmabiz.com	100%		#665,634	View details
Torrent Pharma	torrentpharma.com	88%	31.6K	#932,209	View details
Cadila Pharmaceuticals Limited	cadilapharma.com	86%	18.5K	#1,452,788	View details
••••••••••	••••••.com	••%	•.•M	#•••••	–
••••••••••	••••••.com	••%	•.•M	#•••••	–
••••••••••	••••••.com	••%	•.•M	#•••••	–

3 companies that operate in the same segment as Intas (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

Company	Description	Founded	Location	Total funding	Revenue	Employees
Inventia Healthcare	Oral solid drug delivery systems are manufactured and developed.	1985	Mumbai, Maharashtra, India	USD 42.49 M	USD 89.42 M	962
Strides Pharma Science	Generic, semi-solid, and liquid dosage forms are manufactured.	1990	Bengaluru, Karnataka, India		USD 508.93 M	5,180
Sun Pharma	Specialty generic pharmaceuticals and APIs are manufactured and marketed.	1983	Mumbai, Maharashtra, India		USD 6.21 B	25,870

• India's 100 Largest Unlisted Companies by FY2024-25 Total Income16 Oct 2026